| Title: |
Intravitreal ranibizumab for myopic choroidal neovascularization: 12-month results |
| Authors: |
Silva, RM; Ruiz-Moreno, JM; Rosa, P; Carneiro, A; Nascimento, J; Rito, LF; Cachulo, ML; Carvalheira, F; Murta, JN |
| Publication Year: |
2010 |
| Collection: |
Hospitais da Universidade de Coimbra: Repositório Institucional dos HUC |
| Subject Terms: |
Inibidores da Angiogénese; Anticorpos Monoclonais; Neovascularização da Coróide; Miopia Degenerativa |
| Description: |
PURPOSE: The purpose of this study was to evaluate the safety and efficacy of intravitreal ranibizumab after 12 months in the treatment of choroidal neovascularization secondary to pathologic myopia. METHODS: This was a prospective, multicenter, consecutive, nonrandomized, interventional case series. The study included 34 eyes of 32 patients with choroidal neovascularization secondary to pathologic myopia; 13 eyes had previous photodynamic therapy, and 21 eyes had no previous treatment. The patients were followed for > or = 12 months. Best-corrected visual acuity, optical coherence tomography, and the presence of metamorphopsia were assessed monthly. RESULTS: Mean visual acuity improved 8 letters from baseline to 12-month follow-up, and the difference was statistically significant (P < 0.001): 100% of the eyes lost or=3 lines, 44% improved > or = 2 lines, 65% improved > or = 1 line, and 79% improved > or = 0 lines. Central retinal thickness decreased significantly from baseline to the 12-month follow-up (P < 0.01). A mean of 3.6 treatments were performed during the 12-month follow-up, and no systemic or ocular side effects were registered during that time. CONCLUSION: One-year results of intravitreal ranibizumab for myopic choroidal neovascularization are very promising. Additional prospective studies are necessary to better determine long-term efficacy and safety. |
| Document Type: |
article in journal/newspaper |
| File Description: |
application/pdf |
| Language: |
English |
| Relation: |
https://hdl.handle.net/10400.4/1721 |
| Availability: |
https://hdl.handle.net/10400.4/1721 |
| Accession Number: |
edsbas.4BAD21B2 |
| Database: |
BASE |